kidney stones and glp-1 Renal effects of receptor agonists tirzepatide in individuals with type 2 diabetes: seeds of a promising future | Endocrine Semaglutide and Kidney Stones: Know

Full page ad in NY Times today Oct 28 at 10:21 AM Relevant people Log in or sign up Join the most interesting and insightful discussions.

Understanding how the medication works, how responses vary, and what to watch for early on empowers you to engage confidently with your care plan

If you want simple ideas you can portion ahead, this roundup of healthy snacks for weight loss fits the same practical, low-fuss approach

The SELECT trial, published in 2024, showed that semaglutide reduced major adverse cardiovascular events (MACE: heart attack, stroke, cardiovascular death) by 20% in individuals with obesity, even independent of weight loss magnitude. Why

Emerging Metabolic Therapies Advancements in metabolic health continue to evolve, including therapies that target GLP-1 and GIP pathways

Clinical trials consistently show substantial waist circumference decreases as part of overall weight loss